Figure 3: Tofacitinib suppressed imiquimod induced skin inflammation. (A) Imiquimod was applied to the shaved back and one ear of each BALB/c mouse as described in Figure 2. These mice also received prophylactic treatment of either twice daily 30 mg/kg tofacitinib orally, twice weekly anti-p40 Ab or vehicle control starting on Day 0. Ear thickness was measured on Day 5; results are reported as mean ± SEM with n=10 for each treatment group. (B and C) Representative images of H&E and pSTAT3 stained ear sections from mice treated with tofacitinib and anti-p40 Ab. (D) At study termination, real time RT-PCR on RNA isolated from individual mouse ears from each group for indicated cytokines. Results reported as means ± SEM. All data represent the mean of at least two independent experiments n=10 for each group. E) Cytokine ELISA on protein isolated from individual mouse ears from each group for each indicated cytokine. Results reported as means ± SEM.